Evidence map›Paper›PMID 42864656›Full record

Trial reportJournal of clinical apheresis2026

Plerixafor and G-CSF Versus Placebo and G-CSF in Moderately Mobilizing Patients With Multiple Myeloma to Optimize Hematopoietic Stem Cell Collection Results (OPTIMIZE).

Worel Nina, Schreder Martin, Tanzmann Andreas, Kurz Martin, Huber-Kraßnitzer Bianca, Neumeister Peter, Rosskopf Konrad, Sareban Nazanin, Branka Manuela, Kolovratova Vera and 8 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical apheresis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Worel NinaDepartment of Transfusion Medicine and Cell Therapy, Medical University Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0002-3599-8099
Schreder MartinDepartment of Internal Medicine I, Center for Oncology and Hematology, Clinic Ottakring, Vienna, Austria.ORCID https://orcid.org/0000-0002-1699-9715
Tanzmann AndreasDepartment of Transfusion Medicine and Cell Therapy, Medical University Vienna, Vienna, Austria.
Kurz MartinDepartment of Transfusion Medicine and Cell Therapy, Medical University Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0002-2002-8284
Huber-Kraßnitzer BiancaDivision of Hematology, Medical University of Graz, Graz, Austria.
Neumeister PeterDivision of Hematology, Medical University of Graz, Graz, Austria.
Rosskopf KonradDepartment of Blood Group Serology and Transfusion Medicine, Medical University of Graz, Graz, Austria.
Sareban NazaninDepartment of Blood Group Serology and Transfusion Medicine, Medical University of Graz, Graz, Austria.
Branka ManuelaDepartment of Transfusion Medicine and Cell Therapy, Medical University Vienna, Vienna, Austria.
Kolovratova VeraDepartment of Transfusion Medicine and Cell Therapy, Medical University Vienna, Vienna, Austria.
Oesterreicher SophiaDepartment of Transfusion Medicine and Cell Therapy, Medical University Vienna, Vienna, Austria.
Koerbler BeatrixDepartment of Transfusion Medicine and Cell Therapy, Medical University Vienna, Vienna, Austria.
Kitzweger ElviraDepartment of Internal Medicine II, Clinic Donaustadt, Vienna, Austria.
Ruckser ReinhardDepartment of Internal Medicine II, Clinic Donaustadt, Vienna, Austria.
Rabitsch WernerDepartment of Internal Medicine 1, BMT-Unit, Medical University of Vienna, Vienna, Austria.
Agis HermineDepartment of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0002-1125-0211
Krauth MariaDepartment of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.
Greinix Hildegard TDepartment of Internal Medicine 1, BMT-Unit, Medical University of Vienna, Vienna, Austria.

Funding

Sanofi Genzyme
6 · The paper itself

Abstract

Efficient collection of hematopoietic progenitor cells (HPCs) is essential for autologous stem cell transplantation (ASCT) in multiple myeloma (MM). Although plerixafor is routinely used in poor mobilizers, its role in patients with intermediate mobilization capacity remains unclear. In this randomized, double-blind, placebo-controlled phase IV trial, MM patients with peripheral blood (PB) CD34

Indexed as

BenzylaminesCyclamsGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHeterocyclic CompoundsMultiple MyelomaAdultAgedAntigens, CD34Double-Blind MethodFemaleHematopoietic Stem CellsHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedAntigens, CD34BenzylaminesCyclamsGranulocyte Colony-Stimulating FactorHeterocyclic Compoundsplerixaforautologous stem cell transplantationcolony‐forming unitshematopoietic stem cell mobilizationmultiple myelomaplerixaforstem cell graft composition

Identifiers

PMID42864656
PMCPMC13658576

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.